VORAFET研究:vorasidenib治疗IDH突变胶质瘤的纵向PET RANO 1.0与RANO 2.0缓解评估
VORAFET纵向研究纳入39例未接受过放化疗的IDH突变胶质瘤成人患者,在vorasidenib治疗期间每3个月进行[¹⁸F]FET PET/MRI。PET RANO 1.0评估的ORR为60.9%,中位首次缓解时间4.5个月;RANO 2.0未发现完全或部分缓解,仅5例达轻微缓解。PET RANO 1.0可发现RANO 2.0未反映的代谢变化,但随访尚短,其临床意义有待明确。
要点
- PET RANO 1.0在vorasidenib治疗中可早期发现代谢缓解,ORR达60.9%。
- RANO 2.0基于MRI未观察到完全或部分缓解,仅5例轻微缓解。
- PET进展者更常见细微强化且基线FLAIR体积、MTV、TBRmax、TBRmean更高。
核心结论
- PET RANO 1.0可识别vorasidenib治疗期间的代谢变化,这些变化并不总能被RANO 2.0评估反映。
- PET代谢变化与MRI表现的关系及其临床意义尚需更长随访明确。
研究设计与样本
- VORAFET为纵向研究,纳入39例接受vorasidenib治疗的成人IDH突变胶质瘤患者。
- eligible患者主要为非强化WHO 2级或3级胶质瘤,且未接受过放疗或化疗。
- 主要终点为按PET RANO 1.0和RANO 2.0评估的纵向代谢与结构影像缓解。
- 基线及每3个月进行整合[¹⁸F]FET PET/MRI检查。
主要发现
- 基线时分别有23例和29例患者具有PET和MRI可测量病灶。
- PET RANO 1.0最佳缓解为2例完全缓解和12例部分缓解,ORR为60.9%。
- PET RANO 1.0中位首次缓解时间为4.5个月(范围3-12个月)。
- RANO 2.0无完全或部分缓解,5例达轻微缓解,中位时间9个月(范围6-12个月)。
- PET RANO 1.0判定疾病进展6/39例(15.4%),RANO 2.0判定1/39例(2.6%)。
关键数值与推荐
- PET RANO 1.0最佳缓解:完全缓解2例、部分缓解12例,ORR 60.9%。
- PET RANO 1.0中位首次缓解时间4.5个月(范围3-12个月)。
- RANO 2.0:无完全或部分缓解,轻微缓解5例,中位时间9个月(范围6-12个月)。
- 疾病进展:PET RANO 1.0为6/39例(15.4%),RANO 2.0为1/39例(2.6%)。
临床怎么用
- 对vorasidenib治疗的IDH突变胶质瘤患者,可考虑纵向[¹⁸F]FET PET/MRI辅助评估代谢缓解。
- PET RANO 1.0可发现MRI尚未显示的代谢变化,但不宜单独据此改变临床决策。
- PET进展且伴细微强化或基线高FLAIR体积、MTV、TBRmax、TBRmean者需密切随访。
局限性
- 随访时间尚短,PET代谢变化能否预测后续MRI进展或临床结局尚不明确。
- 样本量有限(39例),基线具有PET和MRI可测量病灶者分别为23例和29例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Conventional MRI may not fully reflect the biological activity of vorasidenib. PET may detect treatment-related metabolic changes before structural changes become evident on MRI. We evaluated longitudinal PET and MRI changes in patients with IDH-mutant gliomas receiving vorasidenib. METHODS: VORAFET is a longitudinal study of adults with IDH-mutant gliomas treated with vorasidenib. Eligible patients had predominantly non-enhancing WHO grade 2 or 3 gliomas, had not received prior radiotherapy or chemotherapy. The primary endpoint was longitudinal metabolic and structural imaging response according to PET RANO 1.0 and RANO 2.0. Integrated [¹⁸F]FET PET/MRI was performed at baseline and every 3 months. RESULTS: Thirty-nine patients were included; at baseline, 23 and 29 had PET and MRI-measurable disease. As best response, PET RANO 1.0 identified 2 complete and 12 partial responses, yielding an ORR of 60.9%; median time to first response was 4.5 months (range 3-12 months). RANO 2.0 showed no complete or partial responses, whereas 5 patients achieved minor response at a median of 9 months (range 6-12 months). Progressive disease occurred in 6 of 39 patients (15.4%) according to PET RANO 1.0 and in 1 of 39 (2.6%) according to RANO 2.0. Patients with PET-PD more often had subtle contrast enhancement and showed higher baseline FLAIR volume, MTV, TBRmax, and TBRmean. CONCLUSIONS: PET RANO 1.0 identified metabolic changes during vorasidenib treatment that were not always reflected by RANO 2.0 assessment. Longer follow-up is needed to clarify the relationship between PET metabolic changes and MRI findings and to determine their clinical significance. Vorasidenib is a new treatment for some patients with IDH-mutant grade 2 gliomas. MRI is the standard test used to follow these tumors, but changes can take time to appear. In this study, 39 patients treated with vorasidenib were followed with both MRI and FET PET. PET often showed treatment-related changes that were not yet visible on MRI. It also identified possible progression in some patients whose MRI was still stable. However, follow-up is still short, and we do not yet know whether these PET changes predict later MRI progression or clinical outcome.
引用
- Lombardi G, Bosio A, Librizzi G, et al. Longitudinal PET RANO 1.0 and RANO 2.0 response assessment in vorasidenib-treated IDH-mutant gliomas: the VORAFET study. Neuro Oncol. 2026. PMID: 42960869. doi:10.1093/neuonc/noag273
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。